Unapproved New Drugs: FDA Warning Letter to OrganiCare, LLC / OrganiCare Nature’s Science, LLC, 2026-10-01
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs
TL;DR
Here's the summary: The FDA Center for Drug Evaluation and Research (CDER) issued a warning letter to OrganiCare, LLC / OrganiCare Nature's Science, LLC on October 1, 2026 (Reference 734925) regarding unapproved new drug violations for "HClear for him" and "FemiClear Genital Herpes Symptoms" products sold via femiclear.com and social media accounts. The products are marketed with claims of treating genital herpes symptoms (e.g., "kills 99.9% of herpes simplex viruses," ">90% of users reported less severe outbreaks") without FDA approval, violating sections 301(d) and 505(a) of the FD&C Act; the FDA stated no over-the-counter drug product has been approved for treatment or prevention of any sexually transmitted infection. The agency warned that consumers relying on these unapproved products may delay appropriate medical care, risking severe complications including infertility, sepsis, and death, and may unknowingly transmit infections to partners.
Argus analysis
# FDA Warning Letter Analysis: OrganiCare, LLC
**The Company and Violations**
OrganiCare, LLC and OrganiCare Nature's Science, LLC, operating the website femiclear.com, received a warning letter from FDA's Center for Drug Evaluation and Research (CDER) on October 1, 2026. The company markets two products—"HClear for him" and "FemiClear Genital Herpes Symptoms"—as treatments for genital herpes symptoms. FDA found these products are unapproved new drugs sold directly to consumers for sexually transmitted infection treatment. The agency emphasized that unapproved STI products pose serious public health risks, as consumers may delay appropriate medical care, increasing risks of infertility, sepsis, and death, while potentially transmitting infections unknowingly to partners.
**Regulatory Citations and Meaning**
The violations center on sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(a) and 331(d)), which prohibit introducing unapproved new drugs into interstate commerce. Additionally, section 201(g)(1) (21 U.S.C. 321(g)(1)) defines the products as drugs based on claims to diagnose, cure, or treat disease. FDA's review identified problematic labeling and marketing claims across the website and social media—including statements that products "kill 99.9% of herpes simplex viruses," provide "fast relief," and claims that "over 90% of users reported less severe outbreaks." Customer testimonials describing symptom elimination also evidenced drug intent.
**Response Timeline and Industry Outlook**
OrganiCare must submit a written response within 15 business days to FDAAdvisory@fda.gov, detailing corrective actions and preventative measures. Compliance officers in the OTC and homeopathic product sectors should monitor whether the company removes these products from market, modifies claims to exclude disease treatment language, or pursues formal drug approval pathways. FDA's footnote clarifying that homeopathic products receive no exemption from standard drug requirements signals intensified enforcement in this category. Failure to respond adequately may result in seizure or injunction actions.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER OrganiCare, LLC / OrganiCare Nature’s Science, LLC MARCS-CMS 734925 — October 01, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Caroline Goodner Recipient Title Chief Executive Officer OrganiCare, LLC / OrganiCare Nature’s Science, LLC 3900 Drossett Dr., Bldg 5, Suite G Austin , TX 78744 United States hello@femiclear.com (b)(6) Issuing Office: Center for Drug Evaluation and Research (CDER) United States October 1, 2026 WARNING LETTER Reference Number: 734925 To Caroline Goodner: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https://femiclear.com/, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. As discussed below, the “HClear for him” and “FemiClear Genital Herpes Symptoms” products available for purchase on your website are unapproved new drugs. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and/or their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional. FDA Review Violations were identified and documented during a review of your website https://femiclear.com/ in July 2026. We have also reviewed your Facebook and Instagram accounts at https://www.facebook.com/FemiClear and https://www.instagram.com/femiclear, respectively, where you direct consumers to your https://femiclear.com/ website to purchase your products. Based on our review, “HClear for him” and “FemiClear Genital Herpes Symptoms” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- Has OrganiCare, LLC / OrganiCare Nature’s Science, LLC had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for OrganiCare, LLC / OrganiCare Nature’s Science, LLC as of 2026-10-06. Argus ingests new FDA enforcement records daily.
- What FDA violations was OrganiCare, LLC / OrganiCare Nature’s Science, LLC cited for?
- The FDA Warning Letter to OrganiCare, LLC / OrganiCare Nature’s Science, LLC (issuing office: Center for Drug Evaluation and Research (CDER)) cites: Unapproved New Drugs. Classification: Unapproved drug.
- When did FDA issue the warning letter to OrganiCare, LLC / OrganiCare Nature’s Science, LLC?
- FDA issued the letter (MARCS-CMS 734925) on 2026-10-01 and posted it publicly on fda.gov on 2026-10-06.
- Is the FDA warning letter to OrganiCare, LLC / OrganiCare Nature’s Science, LLC publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/organicare-llc-organicare-natures-science-llc-734925-10012026.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Unapproved New Drugs: FDA Warning Letter to OrganiCare, LLC / OrganiCare Nature’s Science, LLC, 2026-10-01. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-organicare-llc-organicare-nature-s-science-llc-2026-10-01-unapproved-drug
"Unapproved New Drugs: FDA Warning Letter to OrganiCare, LLC / OrganiCare Nature’s Science, LLC, 2026-10-01." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-organicare-llc-organicare-nature-s-science-llc-2026-10-01-unapproved-drug.
Argus HQ Research. "Unapproved New Drugs: FDA Warning Letter to OrganiCare, LLC / OrganiCare Nature’s Science, LLC, 2026-10-01." Digital Empire Holdings LLC. Accessed October 8, 2026. https://argushq.ai/fda/warning-letter/fda-wl-organicare-llc-organicare-nature-s-science-llc-2026-10-01-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_organicare_llc_organicare_nature_s_science_llc_2026_10_01_unapproved_drug_2026,
title = {Unapproved New Drugs: FDA Warning Letter to OrganiCare, LLC / OrganiCare Nature’s Science, LLC, 2026-10-01},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-organicare-llc-organicare-nature-s-science-llc-2026-10-01-unapproved-drug},
note = {Accessed: October 8, 2026}
}